FDA Announces Need for New Regulatory Pathway for CBD
The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.
Promising 6-Month Interim Results Reported for Treatment-Resistant Schizophrenia
The ongoing study demonstrated statistically significant improvements over baseline in comparison to results at 6 weeks.
Dementia in the News
What's the latest in dementia?
Positive Phase III Study Results Reported for Bipolar I Disorder Treatment in Adults
The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.
Psychopharmacology Conference Offers New Research, Prescribing Tips
Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!
Study Debunks Association Between In Utero Antidepressant Exposure and ADHD Risk
The investigators suggested that future research explore the connection between ADHD risk in children and depression in pregnant parents.
Rolling NDA Submission of Zuranolone for MDD, PPD is Completed
This latest submission completes the FDA filing that was initiated in May.
Phase 1 Study of Apimostinel for Depression Doses First Participants
The drug is in development for the treatment of acute depressive disorders and depression with suicidality.
AMA Announces New Policies Supporting Reproductive Health Care Rights
Policies include opposition to government involvement in medical practice and support of access to abortion care.
Study Identifies Promising Potential Treatment for Alzheimer Disease
Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.
Motivating and Empowering Patients With Schizophrenia
Experts share the benefits of motivational interviewing when working with this patient population—and how clinicians can incorporate it into their practice.
Bipolar I vs Bipolar II: What are the Major Differences in Presentation and Treatment?
An expert discusses key differences and some ways to avoid missing the appropriate diagnosis in these patient populations.
Study Explores Impact of Circadian Pathway, Insomnia Risk Genes on Sleep Disturbance in Autism
Connections between autism risk, sleep disturbances, insomnia risk genes and circadian pathways were analyzed.
New Scholarship Announced for Underrepresented Racial and Ethnic Groups
The American Academy of Psychiatry and the Law scholarship aims to foster a welcoming and supportive environment for forensic psychiatrists of color.
Study Explores Effects of Experimenter Sex on Ketamine Response
The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.
Study Shows Connection Between ADHD Medication and Risk of Suicide Attempt
Risk of suicide attempt is higher among adults, women.
Eisenhower Fellowships Launches 2022 USA Justice Program With Psychiatric Fellow
Cohort includes professionals from multiple fields, including psychiatry and medicine.
$5.3 Million in Grants Awarded to Address Youth Mental Health Crisis
Inaugural recipients will use funds to support infrastructure, student mental health, and programs for children with behavioral challenges.
Migraine and Mental Health: Patients, Health Care Professionals Share Their Perspectives
Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.
Brain Inflammation May Link Alzheimer Disease With Sleep Disturbance
Study shows promising results for early detection and prevention efforts.
Social Determinants of Mental Health and Clinical Updates Featured at Meeting
Did you miss the American Psychiatric Association 2022 Annual Meeting? We've got you covered.
Complementary Effects of Combined Alternative Treatments on Social Anxiety Disorder
Treatments alter the neural processes underlying SAD symptoms.
New Chemical Entity Improves Symptoms in Individuals With Treatment-Resistant Schizophrenia
Interim study results show 77% treatment response rate among participants.
The Youth Mental Health Crisis: Supporting Patients With ASD and ADHD
How can we help this unique patient population thrive? Experts weigh in at the 2022 APA Annual Meeting.
Willpower and ADHD
Experts discuss the role of motivation and willpower in ADHD at the 2022 APA Annual Meeting.
Neurological and Neuropsychiatric Complications of COVID-19
An expert discusses the effects of long COVID on the brain at the 2022 APA Annual Meeting.
Cults in the Age of Influence
Experts discuss appropriate interventions for patients who are victims of undue influence at the 2022 APA Annual Meeting.
Leading the Artificial Intelligence Revolution
Experts discuss psychiatry’s role in the advancement of AI technologies at the 2022 APA Annual Meeting.
Assessing Gaps and Opportunities in ECT, rTMS, and DBS Guidelines
The 2022 APA Annual Meeting highlights the latest guidelines for these treatments, plus recommendations for updates and improvements.
Clearing the ‘Brain Fog’ in Long COVID
Experts address cognitive dysfunction found in patients with long COVID at the 2022 APA Annual Meeting.
2 Clarke Drive Cranbury, NJ 08512